|
Key obesity data from Eli Lilly, Boehringer Ingelheim and Sciwind Biosciences captivated ADA 2026 attendees.
|
 |
|
The authorisation covers combination use with miglustat, or as a single therapy if miglustat cannot be tolerated.
|
|
|
The partnership includes a five-year licence for Owkin’s K Pro, an AI platform designed to augment drug discovery.
|
|
|
The Regeneron-partnered biotech is currently progressing its lead asset, zolucatetide, in desmoid tumours.
|
|
|
In this episode, two oncology analysts share their insights from the ASCO show floor, while talking through the readouts that excited them most.
|
|
